Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kane Biotech Inc

KNE.V ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

TSX · Healthcare · Pharmaceuticals ·

Canada Micro Cap Analyst: N/A

Last Close

$0.02

▲ +0.00%

Market Cap $4.40M · Vol 5.00K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.40M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

60.00

Momentum

Beta

0.29

vs Market

52W High

$0.04

40.33% below

52W Low

$0.01

99.08% above

Volume

5.00K

Avg 143.33K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

59.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Kane Biotech Inc (KNE.V) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KNE.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

YTD

-25.00%

-61.44%

-83.78%

Financials & Valuation

TTM · Annual

Total Revenue	$311.77K
Net Income	$-1,982,833.00
Revenue Growth (YoY)	-70.91%
Gross Margin	-0.15%
Operating Margin	-620.25%
Net Profit Margin	-636.00%
ROE	N/A
ROA · ROIC	-108.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	15.17
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	205.21M

Technical Indicators

50-Day SMA	$0.02
200-Day SMA	$0.02
RSI (14)	60.00
Beta	0.29
52-Week High	$0.04
52-Week Low	$0.01

Volume Today	5.00K
Avg Daily Volume (30D)	143.33K
Relative Volume	0.03x
Volatility (10D)	229.60
Volatility (30D)	254.25
Free Float	59.66%

Analyst Consensus

N/A

Current Price $0.02

Mean Target N/A

52W Low$0.01 52W High$0.04

Current

Target

$0.01 $0.04

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG001SLNKV6

ISINCA4838092084

CountryCanada

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +1.04% JNJ Johnson & Johnson -0.19% ABBV AbbVie Inc. +0.20% NVS Novartis AG +0.43% NOVN.S Novartis AG +0.90%

Company Profile

Kane Biotech Inc. is a Canada-based biotechnology company, which is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company’s segments include Animal health, and Human health. It has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The Company's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.